Though retrospective, the findings provide ‘compelling’ evidence that GLP-1 receptor agonists may help prevent development ...

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity ...

Get your weekly dose of the top news that matters in our newsletter.

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

With mounting evidence that an infodemic of disinformation about GLP-1 weight loss medicines has become America's second obesity crisis, the National Consumers League (NCL) – a leading non-profit ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

How can policy makers and health care leaders ensure affordable, equitable access to GLP-1 medications while managing their ...